HEOR Explained is an accessible way to understand what HEOR is, how it’s used, and its impact on people and healthcare systems. A resource for all, created by ISPOR.
ISPOR’s Strategic Plan 2030 is designed to advance the Society’s vision of a world where healthcare is accessible, effective, efficient, and affordable for all.
Through cutting-edge research, dynamic discussions, and real-world case studies, ISPOR 2026 will highlight the latest advancements in HEOR that enhance patient-centered innovation, advance healthcare access, and drive better outcomes for all.
The ISPOR Education Center provides instant access to HEOR education with on-demand programs delivered through a personalized, powerful, and flexible learning platform.
Value in Health is an international, high-impact journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions.
Looking to connect with ISPOR peers around a shared HEOR topic? Check out our selection of Special Interest Groups and Communities of Interest.
APPRAISE: A Tool for Appraising Potential for Bias in Real-World Evidence Studies on Medication Effectiveness or Safety
Use of Real-World Data to Support Economic Evaluations of Tumor-Agnostic Therapies: Challenges Remain
Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Working Group Report
Use of Real-World Evidence in Health Technology Reassessments Across 6 Health Technology Assessment Agencies
https://www.ispor.org/publications/journals/value-in-health/abstract/Volume-28--Issue-1/A-Review-and-Comparative-Case-Study-Analysis-of-Real-World-Evidence-in-European-Regulatory-and-Health-Technology-Assessment-Decision-Making-for-Oncology-Medicines
A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines
Analytical Methods for Comparing Uncontrolled Trials With External Controls From Real-World Data: A Systematic Literature Review and Comparison With European Regulatory and Health Technology Assessment Practice
Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States
Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force
Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps
Scholar One
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now
×